DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Keryx Biopharmaceuticals (NASDAQ: KERX)

12.16 -0.50 (-3.95%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

KERX $12.16 -3.95%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.59
Previous Close $12.66
Daily Range $12.05 - $12.94
52-Week Range $11.53 - $18.48
Market Cap $1.1B
P/E Ratio -12.53
Dividend (Yield) $0.00 (0.0%)
Volume 2,672,946
Average Daily Volume 1,563,236
Current FY EPS -$1.10

Sector

Healthcare

Industry

Drugs

Keryx Biopharmaceuticals (KERX) Description

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Website: http://www.keryx.com/

News & Commentary

Why Keryx Biopharmaceuticals Stock Plunged

Keryx Biopharmaceuticals stock is among today's top losers as its newly-approved iron-based dialysis drug comes with an unexpected warning.

Use Options For a Chance To Buy KERX at a 42% Discount

Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog

Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape

Heavy Volume And Pre-Market Movement For Keryx Biopharmaceuticals (KERX)

4 More Biotech Secondaries Traders Are Watching

5 More Biotech Secondaries Traders Are Watching

Insider Buying Dominates First Full Week of Trading in 2015

UPDATE: MLV & Co Raises PT On Keryx Biopharmaceuticals On Additional Auryxia Growth Potential

Keryx Biopharmaceuticals (KERX): New Analyst Report from Zacks Equity Research - Zacks Equity Resear

Keryx Biopharmaceuticals (KERX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Keryx Driven By Recent Auryxia Launch In The US

See More KERX News...

KERX's Top Competitors

KERX $12.16 (-3.95%)
Current stock: KERX
GILD $104.83 (0.62%)
Current stock: GILD
CELG $119.16 (-1.41%)
Current stock: CELG
AMGN $152.26 (-2.63%)
Current stock: AMGN